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Abstract It has been suggested that N-glycans act as a general
sorting signal for secretory proteins in MDCK cells [Scheiffele et
al. (1995) Nature 378, 96^98]. Human corticosteroid binding
globulin contains six consensus sites for N-glycosylation and is
known to be secreted to the apical side of MDCK cells. Our
results show that wild-type corticosteroid binding globulin is N-
glycosylated when it is recombinantly expressed in MDCK cells.
Six mutants, each lacking one of the N-glycosylation sites, and a
mutant lacking all six N-glycosylation sites were also secreted to
the apical side of MDCK cells in a polarized manner. Thus, the
N-glycans on corticosteroid binding globulin do not act as an
apical sorting signal in MDCK cells.
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1. Introduction
Polarized epithelial cells are able to secrete proteins specif-
ically at the apical or basolateral plasma membrane. The pol-
arized cell line MDCK, for example, secretes clusterin (gp80)
[1], erythropoietin [2] and corticosteroid binding globulin
(CBG) [3] mainly at the apical side whereas other secretory
proteins are secreted approximately equally at both plasma
membrane domains [4^7]. It was recently suggested that N-
linked glycans act as an apical targeting signal for secretory
proteins, based on the observation that growth hormone, nor-
mally secreted randomly from MDCK cells, is secreted mainly
from the apical side after insertion of one or two N-linked
glycosylation consensus sites [8]. In addition, erythropoietin is
normally secreted to the apical side of MDCK cells, but it is
secreted in a non-polarized manner from MDCK cells after
mutagenesis of two distinct N-linked glycosylation consensus
sequences [2]. Similarly, gp80, CBG and N-glycosylated
growth hormone are all secreted mainly from the apical side
of polarized MDCK cells, but after tunicamycin treatment,
are secreted in a non-polarized way [1,3,8]. It has also been
suggested that N-glycans might act as determinants for trans-
port of transmembrane proteins from the trans Golgi network
to the apical plasma membrane [9].
The present study aims at investigating the role of N-gly-
cosylation in the apical secretion of CBG from MDCK cells.
Surprisingly, we found that elimination of the N-glycosylation
sites in CBG either individually or collectively does not a¡ect
its apical secretion.
2. Materials and methods
2.1. Cell culture
MDCK cells (strain II), a kind gift from K. Mostov (University of
California), were maintained and transfected as previously described
[5]. For sorting experiments, 106 cells per well were seeded onto
Transwell ¢lters (Costar Europe, Badhoevedorp, The Netherlands:
pore size 0.4 Wm, diameter 24.5 mm) allowing separate access to the
apical and basolateral membranes. Filters were used for experiments
1^2 days after con£uence as indicated by assessing the tightness of the
monolayer [10]. Under these conditions, monolayers have a transepi-
thelial resistance of V450 6/cm2, measured by a Millicell-ERS volt-
ohmmeter (Millipore Continental Water Systems, Bedford, MA,
USA).
2.2. Antibodies and DNA constructs
A rabbit anti-human CBG antiserum [11] was used for immunopre-
cipitation of wild-type and mutant CBG. The pRc/CMV vector con-
taining cDNA encoding either wild-type human CBG or di¡erent
CBG N-glycosylation mutants [12] was used to generate stable
MDCK clones expressing CBG.
2.3. Metabolic labelling of cells and immunoprecipitation
Con£uent MDCK cells seeded on ¢lters were pre-incubated for 30
min in methionine-free media and thereafter pulse-labelled with 1 ml
labelling medium (MEM without methionine) containing 660 WCi of
[35S]methionine applied to the basolateral chamber. After a 20 min
pulse, the medium was removed and 1 ml of chase medium (MEM
with 10Umethionine concentration) was applied to both the apical
and basolateral chambers. After 4 h chase, the apical and basolateral
media were collected and used for immunoprecipitation. Immunopre-
cipitation was performed as described [5] and the immunoprecipitated
CBG was analyzed using NuPAGE gels (Novex, San Diego, CA,
USA).
2.4. Deglycosylation assays
A N-glycosidase F deglycosylation kit (Boehringer Mannheim,
Mannheim, Germany) was used to study N-glycosylation of CBG.
Tunicamycin was dissolved in DMSO and stored at 320‡C and added
to the labelling and chase medium to a ¢nal concentration of 15 Wg/
ml. Control cells were treated with similar concentrations of DMSO.
3. Results and discussion
3.1. CBG expressed in MDCK cells is N-glycosylated
We have used site-directed mutagenesis and recombinant
expression to investigate the role of N-glycans in the apical
secretion of CBG, expressed in MDCK cells. A series of six
mutants each lacking one of the six N-glycosylation consensus
sites and a mutant lacking all six N-glycosylation consensus
sites were investigated (Fig. 1). All of these mutants have
previously been expressed in CHO cells in order to determine
the usage of individual N-glycosylation sites [12^14]. Clones of
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cells that showed expression of the desired proteins were iden-
ti¢ed after transfection of MDCK cells with a mammalian
expression vector containing a cDNA encoding each of the
seven mutant or wild-type CBG. For each construct, a high-
and a low-expressing clone were chosen for further investiga-
tion.
To determine whether CBG expressed in MDCK cells is N-
glycosylated, we used an immunoprecipitation assay. Trans-
fected cells were pulsed for 20 min with [35S]methionine and
chased for 4 h. Media were collected, immunoprecipitated,
incubated with N-glycosidase F and analyzed on NuPAGE
gels under reducing conditions. The mobility of wild-type
CBG not treated with N-glycosidase F (Fig. 2,lane 2) suggests
an apparent molecular weight between 50 and 70 kDa. The
heterogenous mobility suggests that some of the consensus
sites are only partially utilized resulting in populations of
molecules with slightly di¡erent molecular weights as has
also been observed in CHO cells [13]. Wild-type CBG treated
with N-glycosidase F (Fig. 2, lane 1) also had a heterogenous
mobility probably because occasionally, one or two N-glycans
were not removed by the N-glycosidase F treatment. How-
ever, the N-glycosidase F-treated wild-type CBG has a clearly
higher mobility than a similar untreated sample (compare Fig.
2, lane 1 and 2) showing that CBG expressed in MDCK cells
is N-glycosylated. Immunoreactive material isolated from me-
dia from untransfected cells treated with N-glycosidase F (lane
3) or non-treated (lane 4) is shown for comparison.
3.2. N-Glycosylation of CBG does not determine its apical
secretion from MDCK cells
MDCK clones expressing the di¡erent CBG mutants or
wild-type CBG were grown to con£uence on Transwell ¢lters.
The cells were pulsed for 20 min with [35S]methionine and
chased for 4 h. The apical and basolateral media were col-
lected, immunoprecipitated and analyzed on NuPAGE gels.
Each sample was diluted by a series of 2-fold dilutions and
each dilution was immunoprecipitated seperately and ana-
lyzed on NuPAGE gels. It was assumed that the immunopre-
cipitation was quantitative and the result was quantitated us-
ing a phosphoimager, only if the 2-fold dilution also resulted
in a 2-fold reduction of the signal (Fig. 3).
As shown in Fig. 4A, wild-type CBG is secreted in a pol-
arized way from MDCK cells at an apical/basolateral ratio of
82/18 (S.D. þ 5: n = 6), as previously shown [3]. The deletion
of any one of the six N-glycosylation sites did not change this
apical distribution (Fig. 4B^G) showing that any single N-
glycan is not essential for the apical delivery of CBG. The
CBG mutant lacking all six N-glycosylation sites was also
targeted to the apical side in a manner indistinguishable
from wild-type CBG. This clearly demonstrates that N-glyco-
sylation does not play a role as an apical targeting signal for
CBG in MDCK cells. Each construct was investigated at least
four times, independently of each other and similar results
Fig. 1. N-glycosylation sites in CBG mutants. The location of con-
sensus sites for N-glycosylation in wild-type (A) and mutant pro-
teins (B^H).
Fig. 2. CBG expressed in MDCK cells is N-glycosylated. MDCK
cells were labelled with [35S]methionine, chased for 4 h and the me-
dia were immunoprecipitated. The immunoprecipitates were treated
or not treated with N-glycosidase F (NGase F) and analyzed on
NuPAGE gels under reducing conditions. N-glycosidase F-treated
immunopreciptate from cells expressing wild-type CBG (lane 1)
shows multiple bands (probably due to residual N-glycans) with a
clearly higher mobility than untreated immunoprecipitate from the
same cells (lane 2). This shows that wild-type CBG is N-glycosyl-
ated. N-glycosidase F-treated (lane 3) and untreated (lane 4) immu-
noprecipitate from untransfected MDCK cells are shown as a con-
trol. The positions of molecular weight standards are indicated.
Fig. 3. Immunoprecipitation of CBG is quantitative. MDCK cells
expressing wild-type CBG (lane 1^4) or CBG mutated in all six N-
glycosylation consensus sites (lane 5^8) were grown to con£uence
on ¢lters. The cells were then labelled for 20 min with
[35S]methionine and chased for 4 h and apical (Ap) or basolateral
(Ba) media were collected and individually immunoprecipitated in
various dilutions (in this case U2 and U4) with a ¢xed amount of
antibodies. The immunoprecipitates were analyzed on NuPAGE gels
with our prior reduction, since this gave a more condensed appear-
ance of the heterogenously glycosylated CBG. Only when the dilu-
tion resulted in a corresponding reduction in the signal (as in the
experiment shown), it was assumed that the immunoprecipitation
was quantitative and the result was quantitated using a phosphoim-
ager.
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were obtained with a high- and a low-expressing clone. How-
ever, the mutant lacking all six N-glycosylation sites was ex-
pressed at a reduced level compared to the wild-type CBG
(roughly estimated to 20% of the wild-type expression) as
has also been observed in CHO cells [12]. The DNA sequence
of the mutant in which all six N-glycosylation sites were elim-
inated was re-con¢rmed by DNA sequencing.
It has previously been observed that treatment of trans-
fected MDCK cells expressing CBG with tunicamycin leads
to a reduction in the secretion rate of CBG and causes the
secretion to change from mainly apical to non-polarized [3].
This could be due to N-glycans functioning as the apical tar-
geting signals for CBG [8]. However, as the CBG carrying
mutations in all six N-glycosylation sites is secreted to the
apical side in a manner indistinguishable from wild-type
CBG (this study), this is not the case. To investigate the e¡ect
of tunicamycin on the secretion of CBG carrying a mutation
at all six N-glycosylation sites, clones expressing this mutant
or wild-type CBG were grown to con£uence on ¢lters. The
cells were pre-incubated with tunicamycin (15 Wg/ml) for
30 min and then labelled for 20 min with [35S]methionine
and chased for 4 h, both in the continuous presence of tuni-
camycin. Mock-treated cells, expressing wild-type or mutated
CBG, secreted CBG mainly apically as expected, whereas in
tunicamycin-treated cells, we observed a dramatic reduction
of the secretion of both wild-type CBG and CBG devoid of
N-glycans to a level below the detection limit of our assay
(data not shown). Musto [3] has previously examined the
secretion of wild-type CBG in the presence of tunicamycin
and observed a similar reduction, except that he was able to
show that the small amounts of CBG were secreted in a non-
polarized manner in the presence of tunicamycin. It is at
present unclear why tunicamycin reduces the secretion of
both wild-type CBG and CBG devoid of N-glycans, but we
speculate that a critical component of the specialized apical
targeting machinery is N-glycosylated or otherwise tunica-
mycin-sensitive.
Up until recently, it has been unclear whether one or more
mechanisms exist for apical targeting of secretory proteins.
However, recent data indicate that at least two di¡erent mech-
anisms exist. One group of secretory proteins uses N-glycans
(possibly carrying a speci¢c modi¢cation and/or having a spe-
ci¢c location on the polypeptides) as apical targeting signal.
An example of this is erythropoietin [2] and also growth hor-
mone engineered to carry two N-glycosylation sites [8] seems
to use this mechanism. Another group of proteins including
CBG (this study) and hepatitis B surface antigen [15] are
secreted apically using a di¡erent targeting determinant. It
was shown that neither tunicamycin treatment nor mutagen-
esis of its single N-glycosylation site a¡ected the apical secre-
tion of hepatitis B surface antigen from MDCK cells. The fact
that the secretion of CBG is sensitive to tunicamycin makes
this drug unsuitable for discrimination between these two
groups.
Our results show that the sorting signal responsible for the
apical secretion of CBG from MDCK cells is not related to an
N-glycan structure on CBG and we are currently looking for
apical targeting determinants on this protein, by making chi-
meras between CBG and a non-sorted homologous protein.
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